March 2008

 

CATARACT/ IOL

 

Intravitreal bevacizumab for post-op pseudophakic cystoid macular edema


   

A recent study, published in the January issue of the Journal of Cataract and Refractive Surgery concluded that intravitreal injection of Avastin (bevacizumab, Genentech, San Francisco), although safe, did not result in improved visual function in patients with postoperative CME.

Martin S. Spitzer M.D., University Eye Clinic Tuebingen, Center of Ophthalmology, Eberhard-Karls University, Tuebingen, Germany, and colleagues assessed the efficacy of Avastin (intravitreal bevacizumab) in patients with cystoid macular edema (CME) after cataract surgery (Irvine-Gass syndrome). They analyzed a retrospective case series that comprised 16 eyes of 16 patients with CME after cataract surgery refractory to current standard treatment who received an injection of 1.25 mg intravitreal Avastin. The median duration of CME before treatment with intravitreal Avastin was 14 weeks, the researchers reported. They found that although the mean retinal thickness decreased slightly after intravitreal Avastin, the mean visual acuity remained unchanged. Repeated Avastin injections did not result in a better outcome, the study authors wrote. In addition, other than mild ocular irritation, they found no adverse effects of the intravitreal injections. The researchers added that in contrast to findings in a previous case report, the beneficial effect of vascular endothelial growth factor inhibition in Irvine-Gass syndrome was not observed.

Reported by: EyeWorld News Service

Intravitreal bevacizumab for post-op pseudophakic cystoid macular edema Intravitreal bevacizumab for post-op pseudophakic cystoid macular edema
Ophthalmology News - EyeWorld Magazine
283 110
283 110
,
2016-07-26T13:36:19Z
True, 3